Zoetis Q2 2026 earnings: U.S. companion animal weakness offsets global growth

Zoetis (NYSE: ZTS) reported Q2 2026 revenue of $2.468 billion, compared with $2.474 billion a year earlier—flat on a reported basis and down 1% organically—while GAAP diluted EPS increased 1% to $1.65 from $1.63. GAAP net income declined 5% to $691 million as weakness in the U.S. companion animal business outweighed growth in livestock and international markets, while a lower diluted share count supported per-share earnings.

Core earnings results

For the quarter ended June 30, gross profit declined 1% as cost of sales increased despite essentially unchanged revenue. The GAAP gross margin was approximately 72.7%, down about 40 basis points, while the net margin fell approximately 1.3 percentage points to 28.0%.

Expenses also affected profitability. Restructuring and certain acquisition- and divestiture-related costs rose to $77 million from $30 million, R&D expense increased 4% to $173 million, and interest expense increased 15% to $61 million. These increases were partially offset by a 4% reduction in selling, general and administrative expenses.

Adjusted results excluded a net $90 million related to purchase accounting adjustments, acquisition and divestiture costs, and certain significant items.

Business and segment performance

Zoetis experienced a pronounced geographic and product mix divergence. U.S. segment revenue fell 7%, led by weaker companion animal demand, while international revenue increased 8% on a reported basis and 6% organically. Livestock products grew in both segments and provided an important offset.

Within the U.S. companion animal portfolio, Zoetis cited pressure on its dermatology franchise and Simparica Trio, generic competition affecting Cerenia and Convenia, and lower Librela sales. International companion animal growth was led by parasiticides including Simparica Trio, Revolution and Stronghold, along with diagnostics and the launches of long-acting osteoarthritis therapies Lenivia and Portela.

Lower share count lifted EPS despite declining earnings

The quarter showed a clear divergence between absolute earnings and per-share results. GAAP net income declined 5%, but diluted EPS increased 1%; adjusted net income fell 1%, while adjusted diluted EPS rose 5%.

Weighted-average diluted shares declined to 417.7 million from 445.5 million, a reduction of approximately 6.2%. That lower denominator supported EPS growth even though both GAAP and adjusted net income decreased, meaning the per-share gains did not reflect growth in aggregate quarterly profit.

Full-year 2026 guidance

Zoetis revised its full-year guidance based on the current operating environment. The updated outlook calls for organic operational declines in both revenue and adjusted net income, consistent with continued pressure from the conditions affecting the companion animal market.

The guidance reflects foreign exchange rates as of July 21, 2026. Organic operational measures exclude foreign exchange effects and certain acquisitions and divestitures.

Management’s view

CEO Kristin Peck attributed the companion animal pressure to fewer clinic visits, increased price sensitivity among pet owners and stronger competition in important categories. Management said Zoetis is adjusting its commercial strategy through targeted investments, faster innovation and business development, while relying on portfolio diversification in livestock and diagnostics.

Zoetis also highlighted a pipeline containing more than 12 potential blockbuster candidates across chronic kidney disease, oncology, cardiology, anxiety and obesity. The company defines a blockbuster as a product generating at least $100 million in annual sales. After the quarter ended, Zoetis completed its acquisition of veterinary teleradiology platform VitalRADS, expanding its diagnostics capabilities into imaging interpretation.

Recent insider transactions

The supplied insider data shows 38 purchases involving 96,395 shares and one sale involving 20,000 shares over the preceding six months, for a net purchase of 76,395 shares. The latest purchase records with complete price and value information were three director transactions in May 2026.

These disclosures describe the transactions but do not, by themselves, establish insiders’ views about the company’s future performance.

Risks investors need to watch

• Persistent U.S. companion animal weakness: Lower veterinary clinic visits and pet-owner price sensitivity could continue to pressure volumes and limit the company’s pricing flexibility.
• Competition in major product categories: Zoetis reported heightened pressure on dermatology products and Simparica Trio, generic competition for Cerenia and Convenia, and lower Librela sales. Continued pressure could affect both revenue and product mix.
• Earnings pressure from expenses: Higher restructuring-related costs, R&D spending and interest expense contributed to lower GAAP profit. Although R&D supports the pipeline, these costs can weigh on near-term margins before new products generate material revenue.
• Execution against revised guidance: The updated outlook anticipates declines in organic revenue and adjusted net income. Delivering within the ranges depends on livestock and international growth continuing to offset the weaker U.S. companion animal market.

Summary

Zoetis’ Q2 2026 results reflected a weaker U.S. companion animal market rather than broad-based deterioration across the portfolio. International operations and livestock products continued to grow, but they were not enough to prevent lower net income and compressed margins. The most important issues ahead are whether U.S. companion animal demand stabilizes, whether competitive and generic pressure eases, and whether international, livestock, diagnostics and new products can support the company’s revised full-year outlook.